Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors.
Guan W, Li S, Zhang Z, Xiao H, He J, Li J, He X, Luo J, Liu Y, Lei L, et al. Thorac Cancer. 2022 Oct; 13(20):2844-2853. Epub 2022 Sep 8.